| Distribution | Full List | Categories |
| by Country | by Vaccine |
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Canada |
65.4% 24,683,269 |
13.9% 5,234,583 |
2.7% | 5.4% |
8.1% 3,062k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Israel |
63.4% 5,485,236 |
59.5% 5,147,028 |
0.2% | 0.1% |
0.3% 23k |
|
| Moderna, Pfizer/BioNTech | ||||||
| United Kingdom |
61.6% 41,831,056 |
44.5% 30,209,707 |
1.9% | 2.9% |
4.8% 3,240k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Chile |
61.4% 11,744,468 |
47.7% 9,117,659 |
2.6% | 3.0% |
5.2% 1,001k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Uruguay |
60.7% 2,109,379 |
36.0% 1,248,646 |
2.5% | 4.9% |
7.5% 260k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Bahrain |
60.7% 1,032,832 |
51.3% 872,508 |
1.3% | 1.9% |
3.3% 55k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Mongolia |
57.9% 1,897,956 |
50.9% 1,667,849 |
0.4% | 2.2% |
2.6% 85k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Qatar |
55.6% 1,601,801 |
42.8% 1,232,183 |
1.4% | 2.7% |
4.1% 117k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Hungary |
54.5% 5,260,418 |
41.3% 3,989,525 |
1.3% | 4.2% |
5.5% 530k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| United States |
52.8% 174,674,144 |
44.0% 145,768,367 |
0.9% | 1.6% |
2.4% 7,963k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Finland |
51.4% 2,848,931 |
13.2% 729,128 |
3.3% | 1.9% |
5.2% 286k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Italy |
49.5% 29,949,601 |
23.9% 14,467,292 |
4.7% | 1.8% |
6.2% 3,764k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Belgium |
49.3% 5,712,486 |
27.4% 3,169,664 |
4.1% | 4.6% |
8.4% 971k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Germany |
48.3% 40,475,199 |
26.6% 22,302,188 |
2.6% | 4.8% |
6.8% 5,725k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Denmark |
48.0% 2,777,818 |
26.3% 1,523,596 |
5.8% | 2.3% |
8.1% 466k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Austria |
47.5% 4,279,537 |
24.8% 2,228,818 |
3.1% | 3.8% |
6.6% 598k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| France |
46.5% 30,374,473 |
22.0% 14,371,963 |
3.5% | 2.7% |
6.1% 3,981k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Spain |
46.4% 21,713,840 |
27.8% 13,007,371 |
3.6% | 3.7% |
6.8% 3,160k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Singapore |
46.2% 2,700,446 |
34.0% 1,990,940 |
3.4% | 1.8% |
5.1% 299k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Netherlands |
45.3% 7,759,667 |
23.6% 4,041,858 |
2.2% | 1.5% |
3.6% 613k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Portugal |
44.9% 4,574,997 |
23.4% 2,386,424 |
3.7% | 1.8% |
5.4% 556k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Lithuania |
43.5% 1,183,917 |
29.8% 812,002 |
1.9% | 3.3% |
5.2% 141k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| China |
43.2% 622,000,000 |
15.5% 223,299,000 |
43.2% | 15.5% |
8.0% 114,948k |
|
| CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac | ||||||
| Czechia |
43.1% 4,610,875 |
20.9% 2,238,730 |
2.8% | 3.6% |
6.2% 666k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sweden |
41.6% 4,201,394 |
22.3% 2,250,996 |
2.3% | 3.8% |
6.1% 613k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Greece |
41.3% 4,302,109 |
27.9% 2,911,340 |
2.3% | 4.6% |
6.5% 680k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Poland |
41.1% 15,549,895 |
26.2% 9,929,923 |
2.3% | 4.1% |
6.2% 2,347k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Estonia |
40.0% 530,511 |
24.0% 317,707 |
1.7% | 3.6% |
5.3% 70k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Dominican Republic |
39.4% 4,272,574 |
19.3% 2,097,995 |
2.8% | 6.0% |
8.8% 954k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Serbia |
39.0% 2,656,065 |
33.8% 2,299,681 |
0.8% | 1.9% |
2.7% 185k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Slovenia |
37.4% 778,235 |
26.8% 557,575 |
2.2% | 3.0% |
5.2% 108k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Norway |
36.4% 1,975,770 |
25.0% 1,353,614 |
2.7% | 2.9% |
5.7% 306k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Ireland |
35.7% 1,760,642 |
10.4% 514,808 |
10.1% 499k |
|||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| United Arab Emirates |
35.2% 3,480,415 |
22.1% 2,187,849 |
5.5% 540k |
|||
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Slovakia |
35.0% 1,913,557 |
21.9% 1,194,127 |
1.2% | 2.9% |
4.1% 223k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Croatia |
34.6% 1,419,924 |
18.1% 744,950 |
1.8% | 4.1% |
5.9% 244k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Latvia |
30.4% 574,168 |
23.3% 438,851 |
1.6% | 3.2% |
4.3% 82k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Argentina |
29.3% 13,223,188 |
7.6% 3,420,581 |
3.6% | 0.7% |
4.4% 1,980k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Costa Rica |
27.7% 1,409,778 |
14.5% 740,742 |
3.7% | 1.1% |
4.8% 244k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Brazil |
26.6% 56,479,200 |
11.2% 23,789,007 |
2.8% | 0.3% |
3.1% 6,671k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Turkey |
26.4% 22,268,007 |
16.6% 13,973,218 |
4.8% | 0.7% |
5.5% 4,651k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Morocco |
25.4% 9,368,046 |
20.4% 7,520,331 |
0.1% | 2.9% |
3.0% 1,090k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| South Korea |
24.5% 12,565,269 |
6.4% 3,262,733 |
8.0% | 1.9% |
9.9% 5,072k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Romania |
23.7% 4,567,268 |
21.9% 4,219,071 |
0.6% | 1.1% |
1.5% 280k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| El Salvador |
21.4% 1,384,489 |
15.5% 1,004,438 |
1.9% | 1.4% |
3.3% 211k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| WORLD |
20.9% 1,632,480,374 |
9.5% 737,571,068 |
9.0% | 3.4% | ||
| Panama |
20.6% 891,151 |
10.1% 436,848 |
3.2% | 1.0% |
4.2% 182k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Australia |
20.5% 5,232,353 |
2.7% 698,892 |
2.6% | 0.2% |
2.8% 727k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Mexico |
20.5% 26,422,800 |
11.8% 15,175,659 |
1.7% | 0.8% |
2.4% 3,145k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Mauritius |
19.5% 247,673 |
16.3% 207,569 |
1.0% | 2.7% |
3.8% 48k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Jordan |
19.3% 1,969,242 |
7.7% 782,039 |
0.8% | 1.8% |
2.6% 264k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Kuwait |
19.2% 822,000 |
0.9% 38,000 |
6.2% 266k |
|||
| Pfizer/BioNTech | ||||||
| Cambodia |
18.4% 3,076,775 |
15.5% 2,591,140 |
1.8% | 2.1% |
4.0% 662k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Colombia |
18.3% 9,291,221 |
7.6% 3,875,823 |
2.0% | 0.8% |
2.8% 1,434k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Azerbaijan |
18.2% 1,842,954 |
9.6% 973,392 |
1.9% | 0.3% |
2.3% 230k |
|
| Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Cuba |
17.7% 2,005,691 |
5.2% 591,072 |
2.1% | 3.8% |
6.6% 749k |
|
| Abdala, Soberana02 | ||||||
| Albania |
17.6% 507,764 |
11.6% 334,771 |
0.5% | 0.9% |
1.4% 39k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Japan |
15.2% 19,262,621 |
5.6% 7,113,830 |
3.8% | 1.8% |
5.5% 7,005k |
|
| Moderna, Pfizer/BioNTech | ||||||
| India |
15.1% 207,830,971 |
3.4% 47,474,395 |
1.4% | 0.2% |
1.6% 21,624k |
|
| Covaxin, Oxford/AstraZeneca | ||||||
| Kazakhstan |
13.6% 2,547,363 |
7.6% 1,435,334 |
1.4% | 1.2% |
2.6% 484k |
|
| QazVac, Sinopharm/HayatVax, Sputnik V | ||||||
| Bolivia |
13.5% 1,572,351 |
4.7% 544,871 |
0.8% | 1.0% |
1.8% 209k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Bulgaria |
12.8% 888,892 |
10.3% 713,244 |
0.5% | 0.9% |
1.5% 102k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Russia |
12.7% 18,550,270 |
9.8% 14,356,888 |
0.5% | 0.6% |
1.1% 1,611k |
|
| EpiVacCorona, Sputnik V | ||||||
| North Macedonia |
12.4% 259,395 |
9.3% 193,029 |
0.4% | 1.8% |
2.2% 46k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Trinidad and Tobago |
11.9% 167,027 |
1.3% 18,506 |
2.7% | 1.1% |
3.8% 53k |
|
| Oxford/AstraZeneca | ||||||
| New Zealand |
11.8% 567,188 |
6.7% 324,514 |
1.4% | 1.0% |
2.4% 115k |
|
| Pfizer/BioNTech | ||||||
| Ecuador |
11.6% 2,043,159 |
5.9% 1,038,013 |
1.4% | 0.9% |
2.3% 415k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Peru |
10.8% 3,567,962 |
5.9% 1,962,675 |
1.3% | 1.6% |
3.0% 982k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Sri Lanka |
10.8% 2,317,012 |
2.9% 613,200 |
1.6% | 1.2% |
2.8% 597k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Malaysia |
10.6% 3,435,420 |
4.5% 1,468,689 |
2.5% | 0.9% |
3.4% 1,114k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Equatorial Guinea |
10.6% 148,579 |
7.1% 99,605 |
0.7% |
0.7% 9k |
||
| Sinopharm/Beijing | ||||||
| Lebanon |
10.5% 716,565 |
5.0% 341,907 |
1.7% | 0.5% |
2.2% 151k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Laos |
9.9% 717,648 |
5.6% 404,480 |
0.4% | 1.1% |
1.4% 105k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Moldova |
9.6% 388,808 |
4.2% 167,789 |
0.5% | 1.2% |
1.7% 67k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Tunisia |
8.7% 1,032,192 |
3.2% 373,763 |
1.6% | 0.2% |
1.8% 213k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Oman |
8.5% 435,090 |
3.3% 170,755 |
1.1% | 0.5% |
1.6% 80k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Nepal |
8.4% 2,438,127 |
2.4% 691,494 |
0.9% |
0.9% 253k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Palestine |
8.0% 408,803 |
4.9% 249,272 |
0.6% | 0.3% |
0.9% 44k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bosnia and Herzegovina |
7.7% 252,499 |
1.9% 63,281 |
0.7% | 0.2% |
0.9% 31k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Indonesia |
7.6% 20,904,723 |
4.3% 11,699,021 |
1.0% | 0.1% |
1.1% 2,987k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Thailand |
7.1% 4,948,227 |
2.6% 1,832,589 |
1.8% | 0.6% |
2.4% 1,674k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Timor |
7.1% 93,152 |
0.0% 17 |
0.9% | 0.0% |
0.9% 11k |
|
| Oxford/AstraZeneca | ||||||
| Belarus |
6.5% 610,988 |
3.3% 313,938 |
1.0% | 0.4% |
1.4% 128k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Botswana |
6.4% 150,019 |
0.1% |
0.1% 3k |
|||
| Oxford/AstraZeneca | ||||||
| Algeria |
5.7% 2,500,000 |
0.4% |
0.4% 159k |
|||
| Oxford/AstraZeneca, Sputnik V | ||||||
| Jamaica |
5.5% 163,209 |
1.0% 31,106 |
0.2% | 0.3% |
0.6% 16k |
|
| Oxford/AstraZeneca | ||||||
| Georgia |
5.3% 212,163 |
1.7% 69,197 |
0.8% | 0.4% |
1.3% 51k |
|
| Oxford/AstraZeneca | ||||||
| Kosovo |
5.1% 98,277 |
0.9% |
0.9% 18k |
|||
| Oxford/AstraZeneca | ||||||
| Libya |
4.8% 330,260 |
0.8% |
0.8% 55k |
|||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Iran |
4.7% 3,984,095 |
1.0% 808,786 |
0.5% | 0.2% |
0.7% 550k |
|
| BBIBP-CorV, Covaxin, Oxford/AstraZeneca, Sputnik V | ||||||
| Philippines |
4.7% 5,132,000 |
0.6% |
0.9% 949k |
|||
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Zimbabwe |
4.7% 693,568 |
2.8% 414,635 |
0.0% | 0.2% |
0.2% 34k |
|
| Sinopharm/Beijing | ||||||
| Paraguay |
4.4% 315,186 |
1.5% 104,739 |
0.4% | 0.2% |
0.6% 42k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Honduras |
4.3% 421,925 |
0.6% 57,926 |
0.5% | 0.0% |
0.6% 59k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Sputnik V | ||||||
| Taiwan |
4.1% 985,084 |
0.1% 24,076 |
1.0% | 0.1% |
1.1% 266k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Pakistan |
4.0% 8,908,051 |
1.4% 3,006,048 |
0.8% | 0.2% |
0.9% 1,975k |
|
| CanSino, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Uzbekistan |
3.6% 1,199,354 |
1.3% 443,390 |
1.5% 494k |
|||
| Oxford/AstraZeneca, RBD-Dimer, Sputnik V | ||||||
| Bangladesh |
3.5% 5,823,245 |
2.6% 4,248,068 |
0.0% |
0.0% 30k |
||
| Oxford/AstraZeneca | ||||||
| Ukraine |
3.5% 1,543,263 |
0.7% 287,884 |
0.5% | 0.3% |
0.8% 342k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Namibia |
3.5% 88,649 |
0.6% 14,956 |
0.5% | 0.1% |
0.6% 16k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Togo |
3.3% 270,784 |
0.9% 76,462 |
0.3% |
0.3% 25k |
||
| Oxford/AstraZeneca | ||||||
| Myanmar |
3.3% 1,772,177 |
2.2% 1,222,723 |
0.1% | 0.5% |
0.6% 351k |
|
| Oxford/AstraZeneca | ||||||
| Guatemala |
3.1% 547,657 |
0.8% 136,095 |
0.3% | 0.1% |
0.4% 76k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Egypt |
2.9% 2,997,129 |
0.6% 606,676 |
0.3% | 0.1% |
0.4% 421k |
|
| BBIBP-CorV, Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Senegal |
2.9% 480,311 |
0.9% 152,337 |
0.1% | 0.5% |
0.6% 95k |
|
| BBIBP-CorV, Oxford/AstraZeneca | ||||||
| Ghana |
2.7% 852,047 |
1.2% 376,169 |
0.0% | 1.2% |
1.2% 380k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Rwanda |
2.7% 350,400 |
0.4% 49,696 |
0.0% | 0.4% |
0.4% 50k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cote d'Ivoire |
2.7% 705,051 |
0.3% |
0.3% 79k |
|||
| Oxford/AstraZeneca | ||||||
| Nicaragua |
2.5% 167,500 |
0.0% |
0.0% 1k |
|||
| Oxford/AstraZeneca, Sputnik V | ||||||
| Angola |
2.5% 822,109 |
1.5% 492,266 |
0.2% | 0.3% |
0.6% 198k |
|
| Oxford/AstraZeneca | ||||||
| Guinea |
2.3% 304,716 |
0.8% 98,558 |
0.2% | 0.1% |
0.2% 29k |
|
| Sputnik V | ||||||
| Venezuela |
2.1% 588,066 |
0.5% 151,896 |
0.3% | 0.2% |
0.4% 129k |
|
| BBIBP-CorV, Sputnik V | ||||||
| Malawi |
2.0% 373,577 |
0.1% 13,786 |
0.1% | 0.1% |
0.1% 25k |
|
| Oxford/AstraZeneca | ||||||
| Kenya |
1.8% 987,277 |
0.2% 128,744 |
0.0% | 0.2% |
0.2% 127k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Uganda |
1.8% 803,797 |
0.0% 4,129 |
0.1% |
0.1% 48k |
||
| Oxford/AstraZeneca | ||||||
| Lesotho |
1.7% 36,637 |
0.0% 122 |
0.2% | 0.0% |
0.2% 4k |
|
| Oxford/AstraZeneca | ||||||
| Ethiopia |
1.6% 1,894,717 |
0.0% |
0.1% 60k |
|||
| Oxford/AstraZeneca | ||||||
| Vietnam |
1.6% 1,584,436 |
0.1% 63,636 |
0.3% | 0.0% |
0.3% 293k |
|
| Oxford/AstraZeneca | ||||||
| Armenia |
1.6% 46,503 |
0.4% |
0.4% 13k |
|||
| Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Kyrgyzstan |
1.4% 88,178 |
0.7% 47,400 |
0.2% | 0.2% |
0.4% 26k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Liberia |
1.3% 66,884 |
0.0% 553 |
0.1% | 0.0% |
0.1% 4k |
|
| Oxford/AstraZeneca | ||||||
| Gambia |
1.3% 30,421 |
0.4% 10,389 |
0.1% | 0.4% |
0.4% 10k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Afghanistan |
1.2% 484,737 |
0.5% 177,266 |
0.0% | 0.1% |
0.1% 20k |
|
| BBIBP-CorV, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iraq |
1.2% 494,524 |
0.5% 209,296 |
0.2% | 0.2% |
0.1% 50k |
|
| BBIBP-CorV, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| South Africa |
1.1% 642,946 |
0.8% 480,665 |
0.7% 438k |
|||
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| Gabon |
1.0% 23,260 |
0.5% 10,331 |
0.4% | 0.1% |
0.5% 10k |
|
| Sinopharm/Beijing | ||||||
| Sudan |
1.0% 453,690 |
0.2% 86,153 |
0.1% | 0.1% |
0.2% 75k |
|
| BBIBP-CorV, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Mozambique |
1.0% 320,129 |
0.2% 74,801 |
0.0% |
0.0% 0k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sierra Leone |
1.0% 77,958 |
0.2% 13,831 |
0.1% | 0.0% |
0.1% 6k |
|
| BBIBP-CorV, Oxford/AstraZeneca | ||||||
| Nigeria |
0.9% 1,964,095 |
0.1% 261,670 |
0.0% | 0.1% |
0.1% 242k |
|
| Oxford/AstraZeneca | ||||||
| Guinea-Bissau |
0.9% 18,706 |
0.2% |
0.2% 3k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mauritania |
0.9% 42,333 |
0.2% 6,902 |
0.2% | 0.0% |
0.1% 6k |
|
| BBIBP-CorV, Oxford/AstraZeneca | ||||||
| Tajikistan |
0.9% 83,743 |
0.1% 13,547 |
0.1% | 0.0% |
0.1% 6k |
|
| Oxford/AstraZeneca | ||||||
| Somalia |
0.9% 135,107 |
0.1% 21,441 |
0.0% | 0.1% |
0.1% 11k |
|
| BBIBP-CorV, Oxford/AstraZeneca, Sinovac | ||||||
| Central African Republic |
0.9% 41,095 |
0.0% 1,549 |
0.3% | 0.0% |
0.3% 16k |
|
| Covaxin, Oxford/AstraZeneca | ||||||
| Zambia |
0.8% 141,829 |
0.0% 5,286 |
0.0% |
0.0% 2k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Yemen |
0.7% 221,380 |
0.2% |
0.2% 68k |
|||
| Oxford/AstraZeneca | ||||||
| Niger |
0.7% 172,812 |
0.1% 13,395 |
0.0% | 0.0% |
0.0% 10k |
|
| BBIBP-CorV, Oxford/AstraZeneca | ||||||
| Mali |
0.6% 121,077 |
0.2% 42,141 |
0.1% | 0.0% |
0.1% 18k |
|
| Oxford/AstraZeneca | ||||||
| Madagascar |
0.5% 150,329 |
0.3% |
0.3% 72k |
|||
| Oxford/AstraZeneca | ||||||
| Papua New Guinea |
0.4% 38,176 |
0.1% |
0.1% 7k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Congo |
0.4% 22,623 |
0.3% 15,645 |
0.1% 7k |
|||
| BBIBP-CorV, Moderna, Oxford/AstraZeneca, Sputnik V | ||||||
| Syria |
0.4% 71,519 |
0.2% |
0.2% 33k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Eswatini |
0.4% 35,227 |
0.0% |
0.0% 0k |
|||
| Oxford/AstraZeneca | ||||||
| Cameroon |
0.3% 72,111 |
0.1% 17,069 |
0.0% | 0.0% |
0.0% 7k |
|
| BBIBP-CorV, Oxford/AstraZeneca | ||||||
| Benin |
0.2% 21,834 |
0.0% 4,790 |
0.0% | 0.0% |
0.0% 5k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| South Sudan |
0.2% 17,350 |
0.0% 1,513 |
0.0% | 0.0% |
0.0% 5k |
|
| Oxford/AstraZeneca | ||||||
| Burkina Faso |
0.1% 17,775 |
0.1% |
0.1% 10k |
|||
| Oxford/AstraZeneca | ||||||
| Democratic Republic of Congo |
0.0% 34,330 |
0.0% 2,609 |
0.0% | 0.0% |
0.0% 7k |
|
| Oxford/AstraZeneca | ||||||
| Chad |
0.0% 5,324 |
|||||
| BBIBP-CorV | ||||||
| Saudi Arabia |
*46.3% 16,109,908 |
2.5% 888k |
||||
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Gibraltar |
116.2% 39,133 |
114.9% 38,698 |
0.1% | 0.2% |
0.2% 0k |
|
| Pfizer/BioNTech | ||||||
| Malta |
77.4% 341,941 |
60.0% 265,090 |
2.9% | 5.9% |
8.6% 38k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Falkland Islands |
75.6% 2,632 |
51.0% 1,775 |
0.8% | 1.7% |
2.4% 0k |
|
| Oxford/AstraZeneca | ||||||
| Isle of Man |
73.4% 62,400 |
33.6% 28,591 |
0.7% | 0.1% |
0.9% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Seychelles |
71.8% 70,653 |
67.7% 66,543 |
0.6% |
0.6% 1k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Cayman Islands |
71.4% 46,928 |
59.5% 39,090 |
3.6% | 2.1% |
6.4% 4k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bermuda |
66.2% 41,198 |
57.3% 35,662 |
2.1% | 1.1% |
3.2% 2k |
|
| Pfizer/BioNTech | ||||||
| Iceland |
65.7% 224,191 |
40.6% 138,517 |
9.2% | 9.4% |
13.6% 46k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| San Marino |
64.2% 21,783 |
64.4% 21,865 |
0.5% | 0.8% |
1.4% 0k |
|
| Pfizer/BioNTech, Sputnik V | ||||||
| Jersey |
63.9% 64,541 |
49.5% 50,074 |
3.2% | 0.4% |
3.6% 4k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bhutan |
62.6% 482,716 |
0.1% |
0.1% 0k |
|||
| Oxford/AstraZeneca | ||||||
| Aruba |
62.1% 66,336 |
52.4% 55,933 |
1.7% | 2.5% |
4.3% 5k |
|
| Pfizer/BioNTech | ||||||
| Anguilla |
60.8% 9,119 |
38.8% 5,818 |
0.5% | 2.0% |
2.5% 0k |
|
| Oxford/AstraZeneca | ||||||
| Maldives |
58.1% 314,194 |
33.2% 179,436 |
0.3% | 1.0% |
1.3% 7k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Turks and Caicos Islands |
53.6% 20,760 |
39.8% 15,410 |
8.1% |
8.1% 3k |
||
| Pfizer/BioNTech | ||||||
| Curacao |
53.3% 87,525 |
45.7% 74,928 |
0.7% | 1.4% |
2.1% 3k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Faeroe Islands |
52.6% 25,686 |
30.0% 14,645 |
5.7% | 1.3% |
7.0% 3k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Cyprus |
49.8% 436,280 |
32.2% 282,495 |
3.2% | 3.3% |
6.5% 57k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Guernsey |
49.2% 32,969 |
20.3% 13,618 |
6.0% 4k |
|||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Monaco |
48.0% 18,836 |
38.5% 15,129 |
2.9% | 2.7% |
5.6% 2k |
|
| Pfizer/BioNTech | ||||||
| Sint Maarten (Dutch part) |
45.6% 19,541 |
33.8% 14,498 |
2.3% | 2.4% |
4.7% 2k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Luxembourg |
43.3% 270,860 |
28.1% 175,704 |
2.7% | 5.1% |
7.8% 48k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Liechtenstein |
43.2% 16,479 |
27.4% 10,449 |
5.9% | 1.7% |
7.5% 3k |
|
| Moderna, Pfizer/BioNTech | ||||||
| British Virgin Islands |
40.5% 12,245 |
24.1% 7,289 |
1.1% | 4.2% |
5.3% 2k |
|
| Oxford/AstraZeneca | ||||||
| Saint Kitts and Nevis |
40.4% 21,469 |
18.0% 9,585 |
2.0% | 2.8% |
4.8% 3k |
|
| Oxford/AstraZeneca | ||||||
| Andorra |
39.5% 30,535 |
14.2% 10,938 |
3.8% | 3.4% |
7.2% 6k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Greenland |
37.3% 21,179 |
16.6% 9,409 |
5.8% | 1.6% |
7.3% 4k |
|
| Moderna | ||||||
| Antigua and Barbuda |
35.6% 34,883 |
24.4% 23,844 |
1.0% | 4.5% |
5.5% 5k |
|
| Oxford/AstraZeneca | ||||||
| Barbados |
30.8% 88,373 |
21.8% 62,631 |
1.7% | 0.4% |
2.1% 6k |
|
| Oxford/AstraZeneca | ||||||
| Dominica |
27.9% 20,048 |
24.5% 17,630 |
0.3% | 0.5% |
0.8% 1k |
|
| Oxford/AstraZeneca | ||||||
| Montserrat |
27.8% 1,389 |
23.9% 1,195 |
0.3% | 0.3% |
0.6% 0k |
|
| Oxford/AstraZeneca | ||||||
| Guyana |
27.6% 216,862 |
10.6% 83,729 |
1.3% | 1.3% |
2.6% 20k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Fiji |
26.5% 237,940 |
0.5% 4,599 |
2.1% |
2.1% 19k |
||
| Oxford/AstraZeneca | ||||||
| Montenegro |
23.2% 145,636 |
19.2% 120,328 |
0.6% | 2.1% |
2.8% 17k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Bonaire Sint Eustatius and Saba |
21.8% 5,726 |
6.3% 1,665 |
||||
| Moderna, Pfizer/BioNTech | ||||||
| Suriname |
20.5% 119,956 |
4.5% 26,529 |
5.3% | 0.8% |
6.2% 36k |
|
| Oxford/AstraZeneca | ||||||
| Samoa |
20.3% 40,230 |
0.9% |
0.9% 2k |
|||
| Oxford/AstraZeneca | ||||||
| New Caledonia |
19.4% 55,277 |
16.1% 45,891 |
0.5% | 0.3% |
0.9% 2k |
|
| Pfizer/BioNTech | ||||||
| Belize |
18.2% 72,453 |
4.1% 16,116 |
1.2% | 1.0% |
2.1% 8k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Saint Vincent and the Grenadines |
16.6% 18,417 |
1.2% 1k |
||||
| Oxford/AstraZeneca | ||||||
| Grenada |
16.4% 18,415 |
8.5% 9,514 |
0.4% | 0.4% |
0.9% 1k |
|
| Oxford/AstraZeneca | ||||||
| Saint Lucia |
16.1% 29,655 |
11.2% 20,589 |
0.5% | 0.6% |
1.1% 2k |
|
| Oxford/AstraZeneca | ||||||
| Bahamas |
12.8% 50,292 |
4.5% 17,827 |
0.5% | 1.3% |
1.8% 7k |
|
| Oxford/AstraZeneca | ||||||
| Brunei |
11.9% 51,908 |
2.7% 11,578 |
1.1% | 0.0% |
1.1% 5k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Cape Verde |
8.1% 45,013 |
0.5% 2,930 |
2.4% | 0.0% |
2.4% 13k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sao Tome and Principe |
5.7% 12,374 |
5.3% 11,544 |
1.1% |
1.1% 3k |
||
| Oxford/AstraZeneca | ||||||
| Comoros |
5.0% 43,140 |
4.7% 41,220 |
0.4% |
0.1% 0k |
||
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Solomon Islands |
2.5% 17,000 |
0.5% 3,479 |
0.3% |
0.0% 0k |
||
| Oxford/AstraZeneca | ||||||
| Vanuatu |
1.7% 5,140 |
1.4% |
1.4% 4k |
|||
| Oxford/AstraZeneca | ||||||
| Djibouti |
1.3% 12,547 |
0.9% 8,810 |
0.6% |
0.6% 6k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||